Episode description
Dr. Andrew Wilder is the CEO of Ripple Neuro, a medical device company which specializes in neural interface technology and neuroprosthetics. In this episode, he discusses how the company plans to progress in the next decade, as part of their big 10-year announcement.
Top three takeaways:
- One big advancement that Ripple Neuro is planning to make in the next decade is to hold clinical trials for neuroprosthetic upper limbs, and obtain market clearance for these devices
- As far as the company itself goes, Ripple Neuro will be restructuring itself over the next decade to accommodate markets for both end medical devices and components for medical devices
- Ripple Neuro is constantly seeking those who are passionate about the long-term sustainability of the company, as well as those who have a passion for solving challenges and having an impact on the world
[0:00] Ladan introduces the episode and the guest, Dr. Andrew Wilder
[1:45] Wilder discusses his background, how he became CEO of Ripple Neuro, and what the mission of Ripple Neuro is
[5:15] Ripple’s goal for the next few decades is to continue to provide solutions in the neuroscience space that can inform therapies for patients with neurological disorders
[8:15] Ripple plans on doing clinical trials with prosthetic limbs over the next five years, after which the product is projected to receive market clearance
[10:20] Ripple is producing both medical devices and components that other vendors can use in their medical devices, and part of the company’s big announcement is that the company is restructuring itself to accommodate both of these markets
[13:00] Ripple is not about developing solely one type of technology, but rather a continuous pipeline of technologies
[16:30] The company looks for people who are passionate about long-term sustainability of the company, and people who are committed to the idea of having an impact on the world
[19:00] Ripple has always had an expertise in sensing in stimulation, which is what some other companies are starting to work with
[21:45] An impact goal for the next 10 years is to have 10,000 devices implanted in humans